Published in Thromb Haemost on July 01, 1994
Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (1994) 9.06
A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost (1993) 7.92
The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA (1995) 7.31
Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet (1992) 5.59
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet (1994) 5.58
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet (1994) 5.45
Oral contraceptives and the risk of myocardial infarction. N Engl J Med (2001) 5.18
Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med (1995) 5.16
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet (1995) 5.10
End of the line for "third-generation-pill" controversy? Lancet (1997) 4.63
Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med (1977) 4.22
The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ (2009) 4.18
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet (1992) 4.15
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med (1996) 4.11
Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost (2007) 4.09
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet (1995) 4.01
Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia (2009) 3.82
Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation (1994) 3.65
Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost (2006) 3.49
Are randomized clinical trials the only truth? Not always. J Thromb Haemost (2006) 3.34
Increased fetal loss in women with heritable thrombophilia. Lancet (1996) 3.34
Anticoagulants and spinal-epidural anesthesia. Anesth Analg (1994) 3.17
Is publication bias a medical problem? Lancet (1993) 3.04
Arterial thrombosis, intrauterine death and "lupus" antiocoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet (1981) 2.81
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet (1999) 2.77
Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc (1999) 2.71
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med (1993) 2.70
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
Association of markers of systemic inflammation, C reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status. J Epidemiol Community Health (2003) 2.46
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Antipsychotic medication and venous thrombosis. Br J Psychiatry (2001) 2.37
von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen. J Thromb Haemost (2006) 2.33
Activation of coagulation system during air travel: a crossover study. Lancet (2006) 2.32
Mortality in hereditary antithrombin-III deficiency--1830 to 1989. Lancet (1991) 2.31
Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost (2012) 2.30
Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation (1998) 2.26
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA (1999) 2.21
Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients. J Thromb Haemost (2012) 2.17
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost (2005) 2.13
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ (1996) 2.11
Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc (2000) 2.09
Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) Blood (1995) 2.09
Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost (2008) 2.06
Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. J Thromb Haemost (2006) 2.06
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
The family history and inherited thrombophilia. Br J Haematol (1994) 2.03
Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost (2006) 2.01
Seasonal variation of venous thrombosis: a consecutive case series within studies from Leiden, Milan and Tromsø. J Thromb Haemost (2012) 2.01
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet (1995) 2.00
Mortality from venous thromboembolism and myocardial infarction in young women in the Netherlands. Lancet (1996) 1.99
The putative factor IX gene promoter in hemophilia B Leyden. Blood (1988) 1.98
Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet (1993) 1.96
Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med (1999) 1.95
Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut (2001) 1.86
von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost (2006) 1.84
Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A. Haemophilia (2013) 1.84
Thromboxane synthetase inhibition as antithrombotic strategy. Lancet (1981) 1.82
The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol (1996) 1.76
Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet (2003) 1.76
Thrombolytic therapy with streptokinase using a standard dosage scheme. Br Med J (1966) 1.75
Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood (2001) 1.75
Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost (2005) 1.73
Course of the international Normalized Ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon. Br J Haematol (1999) 1.69
The Leiden Thrombophilia Study (LETS). Thromb Haemost (1997) 1.65
The incidence and distribution of CpG----TpG transitions in the coagulation factor IX gene. A fresh look at CpG mutational hotspots. Nucleic Acids Res (1990) 1.64
Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) Stroke (1998) 1.63
Increased end-stage diabetic nephropathy in Indo-Asian immigrants living in the Netherlands. Diabetologia (2002) 1.63
Usefulness of patient interview in bleeding disorders. Arch Intern Med (1995) 1.62
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost (2010) 1.62
High levels of factor IX increase the risk of venous thrombosis. Blood (2000) 1.61
Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J Thromb Haemost (2014) 1.61
Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer (2013) 1.60
Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med (2000) 1.60
Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia (2010) 1.59
Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol (1997) 1.59
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Cerebral haemorrhagic infarction in young patients with hereditary protein C deficiency: evidence for "spontaneous" cerebral venous thrombosis. Br Med J (Clin Res Ed) (1985) 1.58
Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost (1996) 1.58
Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost (2008) 1.57